Entrectinib Shows Activity in Pediatric Brain Tumors and Other Solid Tumors
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
Head and Neck Cancer News
HEAD AND NECK CANCER ADVISOR
High Circulating Levels of Cytomegalovirus DNA Linked to Poor OS in Head and Neck Cancer
Evidence is provided for an association between CMV reactivation and poor OS of patients with head and neck cancer in the setting of high systemic inflammation.
Delivery of Alternating Electrical Fields Increases Cell Membrane Permeability in Glioblastoma Multiforme
The researchers speculated that the delivery of alternating electric fields to GBM cells may facilitate the delivery of chemotherapy.
Contrast-Enhanced MRI Characterization of Brain Cancers
According to researchers, neovascularization is more common in glioblastoma, and extravasation is more common in primary CNS lymphoma.
Gene Signature Predicts Outcomes in HPV-Related Oropharyngeal Cancers
HPV gene signature was associated with outcomes in patients with HPV-related oropharyngeal cancers and could become a prognostic biomarker.
Consequences of HPV-Related Disparities in Head and Neck Cancer
A review article highlighted the racial disparities in head and neck cancer incidence and identified how this relates to HPV infection.
Hybrid Minimally Invasive Esophagectomy Confers Lower Complication Rate
Patients who had hybrid minimally invasive esophagectomy had a lower rate of surgery-related complications than those who had transthoracic open esophagectomy.
Liquid Biopsy of Cerebrospinal Fluid Provides Genomic Info on Brain Tumors
Clinical application of cerebrospinal fluid ctDNA analysis remains unclear.
ASCO Critiques Guideline for HPV Testing in Head and Neck Cancer
ASCO reviewed and critiqued the College of American Pathologists guideline for human papillomavirus testing in head and neck cancer.
Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
Durvalumab with or without tremelimumab deemed safe and effective in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.
Treatment Delays May Mean Worse Survival in Head and Neck Cancer
Prolonged postoperative and radiation intervals were associated with worse survival outcomes in patients with head and neck cancer.
Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
Age and pretreatment comorbidities were shown to impact survival outcomes in patients with locally advanced laryngeal cancer.
Scientists Identify 2 Variables That May Lead to Depression in Head and Neck Cancer
These factors influenced the likelihood of depression in patients not given prophylactic antidepressants.
A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
In a small group of head and neck cancer patients, biweekly doses of cetuximab in the maintenance setting appeared to be more tolerable than weekly doses.
Novel Biomarker COX-2 May Have a Prognostic Role in Nasopharyngeal Carcinoma
The biomarker may be a predictor of response to treatment and cancer progression in nasopharyngeal carcinoma.
Recreational Marijuana May Improve Quality of Life Outcomes in Head and Neck Cancer
Previous studies have demonstrated that patients with head and neck cancer experience high levels of stress, anxiety, and psychosocial distress throughout the course of the disease.
Pazopanib Plus Cetuximab May Be Effective and Well-Tolerated in Head and Neck Cancer
Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.
Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.
Motolimod Combination Therapy Does Not Improve Survival in Squamous Cell Carcinoma of the Head and Neck
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the featured study.
Want to read more?
Please login or register first to view this content.
